Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period

MLA

Mariño, Zoe, et al. “Intravenous Silibinin Monotherapy Shows Significant Antiviral Activity in HCV-Infected Patients in the Peri-Transplantation Period.” Journal of Hepatology, vol. 58, no. 3, Mar. 2013, pp. 415–20. EBSCOhost, https://doi.org/10.1016/j.jhep.2012.09.034.

APA

Mariño, Z., Crespo, G., D, A. M., Brambilla, N., Giacovelli, G., Rovati, L., Costa, J., Navasa, M., & Forns, X. (2013). Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. Journal of Hepatology, 58(3), 415–420. https://doi.org/10.1016/j.jhep.2012.09.034

Chicago

Mariño, Zoe, Gonzalo Crespo, Amato, Massimo D, Nadia Brambilla, Giampaolo Giacovelli, Lucio Rovati, Josep Costa, Miquel Navasa, and Xavier Forns. 2013. “Intravenous Silibinin Monotherapy Shows Significant Antiviral Activity in HCV-Infected Patients in the Peri-Transplantation Period.” Journal of Hepatology 58 (3): 415–20. doi:10.1016/j.jhep.2012.09.034.